Physician profile
Michael A Ladinsky
NPI 1679504872
$31,450.82
in general payments reported to CMS, 2019-2025
58 companies · $3,455 in 2025
The $3,455 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,164 · 2020: $2,931 · 2021: $4,508 · 2022: $5,742 · 2023: $4,439 · 2024: $4,212 · 2025: $3,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,988.97 |
| Education | $117.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,910.83 | 2019-2025 | Evenity, Otezla, Krystexxa |
| Abbvie INC. | $3,902.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,639.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,523.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $2,265.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $1,864.46 | 2019-2025 | Ajovy |
| Lilly USA, LLC | $1,609.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,459.38 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $1,331.10 | 2019-2025 | Vascepa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,177.55 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,154.35 | 2019-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $872.73 | 2020-2025 | Nexletol |
| Pfizer INC. | $840.53 | 2019-2025 | |
| Genzyme Corporation | $413.19 | 2024 | |
| Sanofi-Aventis U.S. LLC | $408.42 | 2020-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ladinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.